A new study published in the journal Alzheimer’s and Dementia reports the results of a multi-stakeholder working group imitative designed to improve the communication of endpoints in trials. The report, which was synthesised following meetings of ‘The Global CEO Initiative on Alzheimer’s Disease’ and refined iteratively thereafter, recommends near term and long-term aims which will help interest parties to evaluate and communicate endpoints more meaningfully. Core priorities generated by the group, which included patient advocates, clinicians, academic experts with experience in AD clinical care and outcome measurement, trial sponsors, and experts in clinical trial design and measurement science centred on 1) improving communication of existing measures and 2) advancing novel patient centred endpoints that align with patient and carer priorities.
Within domain one, improving communication of trial endpoints, the CEO initiative suggested using user responder analyses (identify the proportion of individuals who achieve a clinically meaningful outcome over a defined period) and time savings analyse (a way to estimate how much additional time treatment may provide before a person reaches a meaningful milestone in cognitive or functional decline) to convey effects more meaningfully. They also called for operationalisation of minimal clinically important differences to help align expectations and the development of patient centric communication strategies that are cognizant of diverse needs and perspectives.
In domain two, building novel and complementary endpoints, the Global CEO initiative recommended greater incorporation of patient and care partner input, capturing of individual variability, enhanced validation standards and pro-active dialogue that reflect the shift towards earlier and potentially incrementally beneficial interventions.
A salient feature of the recommendations is the need for early and sustained involvement of people with lived experience across the spectrum of trial phases, and co-designed approaches that foreground the lived experience perspective. Key to achieving this, the consortium argue, is transparent collaboration and coordinated efforts.
More information on this study is available here:
https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.71951
Expert perspectives on the design and communication of endpoints in Alzheimer's disease clinical trials synthesised and presented
02/11/2026